MRNA

Moderna
D

MRNA

Moderna executives and insider trading

Stéphane Bancel reported no open-market purchases or sales over the last twelve months.

Over the last twelve months Moderna's insiders sold 1,073,172 shares for 81.65M USD in 22 sales on the open market, and bought 0 shares in 0 purchases.

Insiders over the last twelve months

Insider sales
22
Shares sold
1,073,172
Value sold
81.65M USD
Insider purchases
0

Insiders buying against selling

Bought on the market
Sold on the market
0
1 week
0
0
1 month
17.01M USD
0
3 months
33.88M USD
0
6 months
72.13M USD
0
1 year
81.65M USD
6.01M USD
2 years
81.85M USD
Sold, decided at the timeSold under a Rule 10b5-1 plan set in advance

Open-market purchases and sales reported on Form 4, by value. Awards, option exercises and shares withheld for tax are not counted. Whether a sale was under a Rule 10b5-1 plan is read from each Form 4 at the SEC (the box exists on filings since April 2023).

Executives and directors

The people who run the company and the directors who reported trades, with what each bought and sold on the open market over the last twelve months. The CEO first, then whoever traded most.

NamePositionAgeShares sold (12 months)Value sold (12 months)Shares bought (12 months)Last saleShares held after
Stephen Hoge President50478,96145.45M USD—15 Oct 20261,675,710
Stephane Bancel Director, Chief Executive Officer—499,24628.72M USD—5 Aug 20266,440,260
James Mock Chief Financial Officer4934,8364.69M USD—10 Sept 202660,829
Shannon Thyme Klinger Chief Legal Officer & Corporate Secretary5520,8271.39M USD—1 Sept 202687,044
Noubar Afeyan Director—33,1161.14M USD—21 May 202613,187
Abbas Hussain Director—6,186278.86K USD—1 May 202612,066

Insider sales and purchases by quarter

How many insider sales and purchases were reported each quarter.

Insider sales Insider purchases

Every insider transaction

Insiders must report every trade in the company's shares to the SEC within two business days, on Form 4. Only purchases and sales are trades on the open market; awards, option exercises, shares withheld for tax and gifts come with pay, and the twelve-month totals leave them out.

DateNameTransactionSharesPriceValueShares held afterFiling
15 Oct 2026Stephen HogeSale39,145220.728.64M USD1,636,565Form 4
14 Oct 2026Stephen HogeSale38,774213.478.28M USD1,599,708Form 4
14 Oct 2026Stephen HogeSale450214.1596.37K USD1,599,258Form 4
15 Sept 2026Stephen HogeSale40,281146.075.88M USD1,562,029Form 4
14 Sept 2026Stephen HogeSale40,294144.135.81M USD1,525,858Form 4
10 Sept 2026James MockSale19,836134.492.67M USD74,375Form 4
10 Sept 2026James MockSale15,000134.492.02M USD59,375Form 4
1 Sept 2026Shannon Thyme KlingerSale3,471139.95485.77K USD74,129Form 4
5 Aug 2026Stephane BancelSale147,47356.218.29M USD6,539,564Form 4
5 Aug 2026Stephane BancelSale124,83856.967.11M USD6,414,726Form 4
5 Aug 2026Stephane BancelSale39,89158.122.32M USD6,374,835Form 4
5 Aug 2026Stephane BancelSale187,04458.7911.00M USD6,187,791Form 4
15 Jul 2026Stephen HogeSale53,33667.603.61M USD1,483,848Form 4
15 Jun 2026Stephen HogeSale53,33651.372.74M USD1,483,848Form 4
4 Jun 2026Shannon Thyme KlingerSale3,47150.00173.55K USD67,468Form 4

Common questions about Moderna's executives and insiders

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.